U.S. Agency Rejects Teva Bid to Extend Patent on Copaxone

Four of Teva's patents on flagship multiple sclerosis drug set to expire next month.

The U.S. Patent Office on Friday rejected a request by Teva Pharmaceutical Industries to extend one of several patents on its flagship multiple sclerosis drug, Copaxone.